BIS:NSD-ProShares UltraShort Nasdaq Biotechnology (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 15.0406

Change

-0.17 (-1.11)%

Market Cap

USD 3.74M

Volume

823.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

-0.06 (-0.81%)

USD 2.59B
SQQQ ProShares UltraPro Short QQQ

-0.06 (-0.81%)

USD 2.59B
ZBIO Zenas BioPharma, Inc. Common S..

-0.22 (-1.28%)

N/A
ZBIO Zenas BioPharma, Inc. Common S..

-0.22 (-1.28%)

N/A

ETFs Containing BIS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.76% 75% C 33% F
Dividend Return 2.61% 25% F 58% F
Total Return -14.16% 75% C 34% F
Trailing 12 Months  
Capital Gain -34.72% 50% F 23% F
Dividend Return 2.81% 25% F 41% F
Total Return -31.91% 50% F 24% F
Trailing 5 Years  
Capital Gain -82.08% 50% F 14% F
Dividend Return 1.13% 75% C 4% F
Total Return -80.94% 50% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 40.70% N/A N/A 88% B+
Dividend Return 41.19% N/A N/A 88% B+
Total Return 0.49% N/A N/A 13% F
Risk Return Profile  
Volatility (Standard Deviation) 618.26% N/A N/A 4% F
Risk Adjusted Return 6.66% N/A N/A 44% F
Market Capitalization 3.74M 25% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.